Usage: Bupropion hydrochloride extended-release tablets are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy was established in multiple controlled trials for both conditions, as defined by the DSM.
Usage: Bupropion hydrochloride extended-release tablets (XL) are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy was demonstrated in multiple controlled trials for both indications.
Usage: Bupropion hydrochloride extended-release tablets are indicated for treating major depressive disorder (MDD) in adults. Efficacy has been demonstrated in controlled trials for both acute episodes and maintaining antidepressant response after initial treatment.
Usage: Bupropion hydrochloride tablets USP are indicated for the treatment of major depressive disorder (MDD) as defined by the DSM, supported by clinical trials demonstrating efficacy in managing major depressive episodes in adults.
Usage: Bupropion hydrochloride extended-release tablets (XL) are indicated for treating major depressive disorder (MDD) and preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy is supported by controlled clinical trials for both conditions.
Usage: Bupropion hydrochloride extended-release tablets (SR) are indicated for treating major depressive disorder (MDD) in adults. Efficacy was established through controlled trials, showing effectiveness in both short-term treatment and maintenance of antidepressant response for up to 44 weeks.
Usage: Bupropion hydrochloride tablets are indicated for the treatment of major depressive disorder (MDD) as defined by the DSM. Efficacy was demonstrated in controlled trials involving adult subjects with MDD.
Usage: Bupropion hydrochloride extended-release tablets (XL) are indicated for treating major depressive disorder (MDD) and for preventing seasonal major depressive episodes in patients with seasonal affective disorder (SAD). Efficacy has been demonstrated in multiple controlled trials for both indications.